Home » Stocks » INBX

Inhibrx, Inc. (INBX)

Stock Price: $36.42 USD 1.29 (3.67%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
Market Cap 1.37B
Revenue (ttm) 10.38M
Net Income (ttm) n/a
Shares Out 26.75M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $36.42
Previous Close $35.13
Change ($) 1.29
Change (%) 3.67%
Day's Open 35.65
Day's Range 34.69 - 37.34
Day's Volume 41,986
52-Week Range 15.96 - 50.00

News

There are no news available yet.

About INBX

Inhibrx, a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. Its therapeutic candidates include INBRX-109, a multivalent agonist of death receptor 5, which is in Phase 1 clinical trials in patients with solid tumors, including sarcomas; and INBRX-105, an antagonist of programmed death ligand 1 (PD-L1) and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with PD-L1 expressing tumors. The company's therapeutic candidates also comprise INBRX-101, an F... [Read more...]

Industry
Biotechnology
IPO Date
Aug 19, 2020
CEO
Mark Paul Lappe
Employees
75
Stock Exchange
NASDAQ
Ticker Symbol
INBX
Full Company Profile

Financial Performance

In 2019, Inhibrx's revenue was $13.21 million, an increase of 53.71% compared to the previous year's $8.60 million. Losses were -$51.40 million, 64.9% more than in 2018.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for Inhibrx stock is "Strong Buy." The 12-month stock price forecast is 37.75, which is an increase of 3.65% from the latest price.

Price Target
$37.75
(3.65% upside)
Analyst Consensus: Strong Buy